Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972771 | 0.95 | OPRM1 (0.80) | OPRM1OPRD1 | |
| SCHEMBL29973283 | 0.95 | OPRM1 (0.80) | OPRM1OPRD1 | |
| SCHEMBL31303185 | 0.94 | OPRM1 (0.78) | OPRM1OPRD1 | |
| SCHEMBL30294044 | 0.93 | OPRM1 (0.77) | OPRM1OPRD1 | |
| SCHEMBL11065582 | 0.87 | OPRD1 (0.67) | OPRM1OPRD1 | |
| SCHEMBL26342858 | 0.87 | OPRM1 (0.72) | OPRM1OPRD1 | |
| SCHEMBL22545413 | 0.87 | OPRM1 (0.60) | OPRM1OPRD1 | |
| SCHEMBL29590990 | 0.87 | OPRM1 (0.67) | OPRM1OPRD1 | |
| SCHEMBL11069657 | 0.86 | OPRD1 (0.65) | OPRM1OPRD1 | |
| SCHEMBL11059764 | 0.86 | OPRD1 (0.68) | OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090085-A1 | TREATMENT OF CD33 RELATED DISEASES AND DISORDERS | EMPIRICO INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-12478585-B2 | Micelles and vesicles for the delivery of glycopeptides | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-11-25 | — | — | US | claimed |
| US-12297227-B2 | Method for extracting target protein from biological sample and method for analyzing target protein | MEDIFORD CORPORATION (JP) | 2025-05-13 | — | — | US | claimed |
| US-12139455-B2 | Polyethylene glycol derivative and use thereof | HANMI PHARM. CO., LTD. (KR) | 2024-11-12 | — | — | US | claimed |
| CN-118209669-A | Solid phase extraction-liquid chromatography-mass spectrometry detection method for small peptide substances in dry blood spots | 北京体育大学 | 2024-06-18 | — | — | CN | claimed |
| US-20230212103-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2023-07-06 | — | — | US | claimed |
| EP-3475417-B1 | COMPOSITIONS AND METHODS FOR MAKING BENZYLISOQUINOLINE ALKALOIDS, MORPHINAN ALKALOIDS, THEBAINE, AND DERIVATIVES THEREOF | ANTHEIA INC (US) | 2023-05-24 | — | — | EP | claimed |
| US-20230139745-A1 | NON-PEPTIDIC POLYMERIC LINKER COMPOUND, CONJUGATE COMPRISING SAME LINKER COMPOUND, AND METHODS FOR PREPARING SAME LINKER COMPOUND AND CONJUGATE | HANMI PHARM. CO., LTD. (KR) | 2023-05-04 | — | — | US | claimed |
| US-20230104480-A1 | MICELLES AND VESICLES FOR THE DELIVERY OF GLYCOPEPTIDES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-04-06 | — | — | US | claimed |
| US-11603346-B2 | Polyethylene glycol derivative and use thereof | HANMI PHARM. CO., LTD. (KR) | 2023-03-14 | — | — | US | claimed |
| US-20010038862-A1 | Topical and transdermal administration of peptidyl durgs using hydroxide releasing agents as permeation enhancers | TECHNOLOGY RECOVERY SYSTEMS, LLC | 2001-11-08 | — | — | US | claimed |
| WO-2001039791-A2 | TYROSINE- AND TRYPTOPHAN-CONTAINING PEPTIDES AS ANTIOXIDANTS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2001-06-07 | — | — | WO | claimed |
| US-6225100-B1 | ENZYME FROM CLOSTRIDIUM WITH STORAGE AND REACTION STABILITY; FOR EFFICIENT SULFATION OF TYROSYLPEPTIDES SUCH AS CHOLECYSTOKININ | DCV, INC. | 2001-05-01 | — | — | US | claimed |
| WO-1998003636-A9 | NOVEL ARYLSULFOTRANSFERASE | — | 1998-05-22 | — | — | WO | claimed |
| WO-1998003636-A1 | NOVEL ARYLSULFOTRANSFERASE | BIO-TECHNICAL RESOURCES (US) | 1998-01-29 | — | — | WO | claimed |
| EP-0820466-A2 | FLUORESCENT PEPTIDES | Advanced Bioconcept Inc. (CA) | 1998-01-28 | — | — | EP | claimed |
| WO-1997004311-A2 | CELL SORTING WITH FLUORESCENT PEPTIDES | ADVANCED BIOCONCEPT, INC. (CA) | 1997-02-06 | — | — | WO | claimed |
| US-5572025-A | Method and apparatus for scanning an ion trap mass spectrometer in the resonance ejection mode | THE JOHNS HOPKINS UNIVERSITY, SCHOOL OF MEDICINE (US) | 1996-11-05 | — | — | US | claimed |
| WO-1996031531-A2 | FLUORESCENT PEPTIDES | ADVANCED BIOCONCEPT, INC. (CA) | 1996-10-10 | — | — | WO | claimed |
| WO-1991008220-A1 | A METHOD FOR THE STEPWISE, CONTROLLED SYNTHESIS OF CHEMICAL SPECIES, PARTICULARLY PEPTIDES, COUPLED PRODUCTS OBTAINED BY THE METHOD AND THE USE OF THESE COUPLED PRODUCTS, E.G. AS VACCINES | HOUEN GUNNAR (DK) | 1991-06-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603346-B2 | Polyethylene glycol derivative and use thereof | UGCG, NAPEPLD, CD44 | OPRM1 2930/4885OPRD1 2067/4885 |
| US-12139455-B2 | Polyethylene glycol derivative and use thereof | RPN2, MPDU1, RPN1 | OPRM1 3014/4885OPRD1 1556/4885 |
| US-12478585-B2 | Micelles and vesicles for the delivery of glycopeptides | CHMP4B, MUC1, EXOSC4 | OPRM1 3730/4885OPRD1 4443/4885 |
| US-20230139745-A1 | NON-PEPTIDIC POLYMERIC LINKER COMPOUND, CONJUGATE COMPRISING SAME LINKER COMPOUND, AND METHODS FOR PREPARING SAME LINKER COMPOUND AND CONJUGATE | FCGR1A, FCGR3B, FCGR2A | OPRM1 4343/4885OPRD1 4706/4885 |
| US-20230104480-A1 | MICELLES AND VESICLES FOR THE DELIVERY OF GLYCOPEPTIDES | CHMP4B, MUC1, EXOSC4 | OPRM1 3730/4885OPRD1 4443/4885 |
| US-20230212103-A1 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | RPN2, MPDU1, RPN1 | OPRM1 3014/4885OPRD1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.